KPMG notifies Aptose it will not stand for re-appointment as auditor; material weakness disclosed

Aptose Biosciences Inc.

KPMG informed Aptose on Apr 15, 2025 it will not seek reappointment for the 2025 annual audit.
KPMG will continue reviewing interim financials through first two fiscal quarters of 2025.
No disagreements between Aptose and KPMG on accounting principles or audit scope.
A previously disclosed material weakness in internal control over financial reporting (warrants) was noted.
Aptose has initiated a process to select a new independent registered public accounting firm.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.